Middle East and Africa Iodinated Contrast Media in Interventional X-Ray Market, By Route of Administration (Intravenous, Oral, Rectal, Others), Indication (Cardiology, Neurology, General Surgery, Oncology, Urology), Agent Type (Non-Ionic, Ionic), End User (Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End Users), Distribution Channel (Direct Tender, Retail Sales and Other) – Industry Trends and Forecast to 2030.
Middle East and Africa Iodinated Contrast Media in Interventional X-Ray Market Analysis and Size
The Middle East and Africa iodinated contrast media in interventional X-Ray market is anticipated to witness huge growth during the forecast period. The occurrence of obesity in adults of 30–60 years in Saudi Arabia increased by 1.5% for women and 4.1% for men over the year between 1992 and 2005. The occurrence of chronic conditions with multiple comorbidities is more among older adults. Increasing preference towards iodinated contrast media from traditional contrast media is increasing the market during the forecast period 2023-2030.
Data Bridge Market Research analyses a growth rate in the Middle East and Africa iodinated contrast media in interventional X-Ray market in the forecast period 2023-2030. The expected CAGR of Middle East and Africa iodinated contrast media in interventional X-Ray market is tend to be around 3.60% in the mentioned forecast period. The market value is USD 3654.3 million in 2022, and it would grow upto USD 4849.4 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Middle East and Africa Iodinated Contrast Media in Interventional X-Ray Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
By Product & Services (Instruments and Devices, Assays and Reagents and Services and Software), Test Type (Traditional Diagnostic Tests, Mechanical Tests, Imaging Tests and Molecular Diagnostic Tests), Diseases (Chronic Obstructive Pulmonary Disease (COPD), Lung Cancer, Asthma, Tuberculosis, Bronchitis, Pulmonary Fibrosis and Other Diseases), End User (Hospital/Clinical Laboratories, Physician Offices, Reference Laboratories and Other End Users), Distribution Channel (Direct Tender, Retail Sales and Other)
|
|
Countries Covered
|
Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA)
|
|
Market Players Covered
|
Bayer AG (Germany), Iso-Tex Diagnostics, Inc. (U.S.), Bracco Diagnostic Inc. (Italy), Novalek Pharmaceuticals Pvt. Ltd. (India), TAEJOON PHARM (South Korea), Unijules Life Sciences Ltd (India), GENERAL ELECTRIC COMPANY (U.S.), Guerbet (France), J.B.Pharma (India)
|
|
Market Opportunities
|
|
Market Definition
Iodinated contrast media in interventional X-ray is important for healthcare practitioners make appropriate clinical and diagnostic decisions across numerous levels of health care services. Iodinated contrast media are the type of contrast agents that contain iodine atoms which are used for x-ray-based imaging modalities such as computed tomography (CT). They can also used in fluoroscopy, angiography and venography, and even rarely, plain radiography. It is used for procedures that involves X-rays, such as CT, coronary angiography, angiography, arthrography, myelography and gastrointestinal fluoroscopic studies. Gadolinium contrast agents are used for MRI studies.
Middle East and Africa Iodinated Contrast Media in Interventional X-Ray Market Dynamics
Drivers
- Increased Technological Advancements
The increasing introduction of digital solutions that help in the management of contrast agent injection is expected to boost the market growth. For instance, Guerbet launched Contrast&Care 2.0 which is a digital solution that connects all CT, Cath laboratory, and MRI injectors and has smart reader and connectivity features, allowing users to scan and read data on their smartphones and computers. Thus, this factor boosts the market growth.
- Increasing Rate of Complex Comorbidities
The growing occurrence of complex comorbidities and long-term diseases has led to an upsurge in diagnostic imaging tests, that involves ultrasound, X-rays, and advanced imaging technology such as MRI & CT scans. For instance, GE Healthcare received the U.S. FDA approval for Clariscan, which is a contrast agent used for macrocyclic MRI in November 2019. These products aid in the identification of the need for perioperative scans before surgeries and treatment in interventional procedures which further boost the market growth.
Opportunities
- Rise in Chronic Diseases
The occurrence of chronic conditions with multiple comorbidities is higher among the elderly adults. The incidence of obesity in adults of 30–60 years in Saudi Arabia increased by 1.5% for women and 4.1% for men yearly between 1992 and 2005. In Qatar and Kuwait, 35% and 36% of male; and 45% and 48% of female adults were found to be obese. In Kuwait, around 21% of males and 18% of females aged 10–19 were obese. The increase in obesity in the middle east countries is likely to have substantively contributed to the increasing rate of diabetes prevalence with an annualized rate of change of 4% in Saudi Arabia and of 2% in Oman. Additionally, the frequency of people with diabetes has increased from 5.9% to 13.7% in this area during the forecast period. Therefore, this factor create more opportunity for the market growth.
- Increased Drug Approvals
Numerous FDA approval for iodinated contrast agent will also increase the commercialization of new iodinated products in the market. As a result, large number of approvals for iodinated agents will aid in the growth of iodinated contrast media in interventional X-Ray market. For instance, the Food and Drug Administration (FDA) approved GE Healthcare Visipaque (iodixanol) imaging agent in March 2017. Therefore, growing drug approvals boost the growth of the market.
Restraints/Challenges
- High Cost
The increased expenditure which is required for setting up these techniques hamper the market growth. Numerous market players make huge investment in manufacturing new and advanced machines to increase the process and in return the cost is increased. Thus, this factor impede the market growth.
This Middle East and Africa iodinated contrast media in interventional X-Ray market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Middle East and Africa iodinated contrast media in interventional X-Ray market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Middle East and Africa Iodinated Contrast Media in Interventional X-Ray Market
During the pandemic, all diagnostic procedures except COVID diagnosis showed a dip in 2020 which largely affected the growth of the market. Diagnosis of heart diseases reduced by nearly two-thirds globally during the early months of the pandemic as countries and patients prioritized COVID-19. In the post pandemic era, the introduction of digital solutions for precise and effective management of contrast agent injection is projected to boost market growth. Numerous studies are showing the fatal effect of COVID on health that causes heart attacks and strokes; this might surge the market growth in the future.
Recent Developments
- In 2019, General Electric and Daiichi Sankyo Company participated into an agreement that Daiichi Sankyo to transfer the authorization of marketing rights for four diagnostic imaging agents in Japan to GE Healthcare. After the completion of this agreement, the company expand their diagnostic imaging agents in the Japan. This will help company to expand their business in the market.
Middle East and Africa Iodinated Contrast Media in Interventional X-Ray Market Scope
The Middle East and Africa iodinated contrast media in interventional X-Ray market is segmented on the basis of route of administration, indication, agent type, end-user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Route of Administration
- Intravenous
- Oral
- Rectal
- Others
Indication
- Cardiology
- Neurology
- General Surgery
- Oncology
- Urology
Agent Type
- Non-Ionic
- Ionic
End User
- Hospital/Clinical Laboratories
- Physician Offices
- Reference Laboratories
- Others
Distribution Channel
- Direct Tender
- Retail Sales
- Other
Middle East and Africa Iodinated Contrast Media in Interventional X-Ray Market Regional Analysis/Insights
The Middle East and Africa iodinated contrast media in interventional X-Ray market is analysed and market size insights and trends are provided by route of administration, indication, agent type, end-user and distribution channel as referenced above.
The major countries covered in the Middle East and Africa iodinated contrast media in interventional X-Ray market report are Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).
UAE dominates the Middle East and Africa iodinated contrast media in interventional X-ray market because of strong healthcare infrastructure base and increased consumption of iodinated contrast media in interventional X-ray. The wide presence of well-established healthcare facilities and easy availability of advanced technologies along with high demand for diagnostic procedures due to disease screening initiatives and disease management in this region is anticipated to increase the number of inpatient examinations.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Middle East and Africa Iodinated Contrast Media in Interventional X-Ray Market Share Analysis
The Middle East and Africa iodinated contrast media in interventional X-Ray market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Middle East and Africa respiratory diagnostics market.
Key players operating in the Middle East and Africa iodinated contrast media in interventional X-Ray market include:
- Bayer AG (Germany)
- Iso-Tex Diagnostics, Inc. (U.S.)
- Bracco Diagnostic Inc. (Italy)
- Novalek Pharmaceuticals Pvt. Ltd. (India)
- TAEJOON PHARM (South Korea)
- Unijules Life Sciences Ltd (India)
- General Electric (U.S.)
- Guerbet (France)
- J.B.Pharma (India)
SKU-